[PDF] scleritis Nov 15 2021 B

View - Download scleritis

Previous PDF

Next PDF

The

Conjunctiva

Up Close,P. 48

Beneath

the Mask: OSD

Issues

Spike Due to Improper Wear,P. 56 Dry Eye: Where Do We Stand with Omega-3 Supplements?,P. 66

Anterior

Blepharitis:

The Front Line of

OSD,P. 74

When Your

Patient

Complains

of Red

Eye,P. 85

- EARN 2 CE

CREDITS

CLQA:

Managing

Scleral

Decentration,P. 94 •URGENT CARE: Open-globe Injuries,P. 100 Get up to speed on the clinical manifestations of countless conditions - and what to do about them. November 15, 2021 • reviewofoptometry.comLeadership in clinical care ffff 34

Eye-Popping

Office

Spaces

17 33
34
25
...34 ...34 34
34
33
32
25
32
25
33

332530

3333242233

33

333333

373627

33

3132241324

3124
33

323333

17 4 33
32
33
24
33
22
133
31
24
33
17 17

1777

4 4

33...†

33

35‰

33
33
Am J Med Genet C Semin Med

Genet.

Š‹ŒŽ‘"‰‚7€‚

S:7" S:5"

T:7.75"B:8"

The

Conjunctiva

Up Close,P. 48

Beneath

the Mask: OSD

Issues

Spike Due to Improper Wear,P. 56 Dry Eye: Where Do We Stand with Omega-3 Supplements?,P. 66

Anterior

Blepharitis:

The Front Line of

OSD,P. 74

When Your

Patient

Complains

of Red

Eye,P. 85

- EARN 2 CE

CREDITS

CLQA:

Managing

Scleral

Decentration,P. 94•URGENT CARE: Open-globe Injuries,P. 100 Get up to speed on the clinical manifestations of countless conditions - and what to do about them. November 15, 2021 • reviewofoptometry.comLeadership in clinical care ffff

Eye-Popping

Office

Spaces

17 33
25
33
32
25
32
25
33

332530

* Pivotal study designs: Two Phase 3, randomized, multicenter, parallel-group studies, APOLLO and LUNAR, evaluating noninferiority of once-daily VYZULTA vs twice-daily

timolol maleate 0.5% in patients with open-angle glaucoma or ocular hypertension. Primary endpoint was IOP measured at 9 assessment time points in study eye. APOLLO

(VYZULTA, n=284; timolol, n=133) and LUNAR (VYZULTA, n=278; timolol, n=136). 2,3

VYZULTA and the V design are trademarks of Bausch & Lomb Incorporated or its a37 liates. Any other product/brand names and/or logos are

trademarks of the respective owners. ©2021 Bausch & Lomb Incorporated or its a37 liates. All rights reserved. VYZ.0258.USA.20VYZULTA Prescribing Information. Bausch & Lomb Incorporated. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol

maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study.

2016;123(5):965-973.

Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini

B, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study.

2016;168:250-259.

BRIEF SUMMARY OF PRESCRIBING INFORMATION

This Brief Summary does not include all the information needed to use VYZULTA safely and effectively. See full Prescribing Information for VYZULTA.

VYZULTA

(latanoprostene bunod ophthalmic solution), 0.024%, for topical ophthalmic use.

Initial U.S. Approval: 2017

1 INDICATIONS AND USAGE

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Pigmentation

5.2 Eyelash Changes

5.3 Intraocular Inffammation

5.4 Macular Edema

5.5 Bacterial Keratitis

5.6 Use with Contact Lens

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

and malrotation, abdominal distension and edema. Latanoprostene bunod was not teratogenic in the rat when administered IV at 150 mcg/kg/day (87 times the clinical dose)

8.2 Lactation

8.4 Pediatric Use

8.5 Geriatric Use

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

13.2 Animal Toxicology and/or Pharmacology

Distributed by:

REVIEW OF OPTOMETRY | NOVEMBER 15, 20214

N o fewer than four new ophthalmic drugs received FDA approval in

October,

and each hopes to distin- guish itself with a unique approach to care.

Retina

specialists will have access to a ranibizumab-dispensing implant for wet age-related macular degenera- tion (AMD) and a suprachoroidal injec- tion to treat uveitic macular edema.

Optometrists

will be able to prescribe the ffrst of several forthcoming eye drops for presbyopia and a nasal spray to treat dry eye.

For the ODs

Corrective

lenses for presbyopia have a new competitor to contend with. The ffrst drug for such use—Vuity, from Al- lergan—has ffnally entered the market. The pupil-constricting drop (pilocar- pine

1.25%)

reaches peak efffcacy one hour after use, then begins to wane.

Patients

begin experiencing visual improvement in as little as 15 minutes, and at least some positive effects can last up to six hours, according to the drug"s FDA trial data.

Dosing

is QD.

Vuity"s

two Phase III trials (Gemini

1 and 2) used a primary endpoint of

achieving three lines of near vision im- provement under mesopic conditions without losing more than one line of distance vision, when measured at day 30,
hour three, of use. This was met by 31%
and 26%
of subjects, respectively, in the two studies. Both groups showed statistically signiffcant improvement over placebo, a press release notes.

Headache

and conjunctival hyper- emia were the most common

adverseevents. Thecompany saysthe drug"svehicle isformulated toadapt to thepH of the eyeto reduce blurand discom-fort.

In a ffrst for dry eye pa- tients, a nasal spray that stimulates the trigeminal parasympathetic pathway offers a new means of boosting tear production.

Tyrvaya

(varenicline

0.03mg,

Oyster

Point

Pharma)

is a cholinergic agonist that triggers basal tear production, the company says.

Patients

gained 10mm or more in

Schirmer"s

scores.

For the MDs

While the average patient with wet age-related macular degeneration (AMD) today is treatedquotesdbs_dbs25.pdfusesText_31

[PDF] B Fleet, l`art de protéger sa flotte - France

[PDF] B G H I D E F C - Ville de Jouy-le

[PDF] B HW gb - Bravilor Bonamat - Électricité

[PDF] b i g s h r i m p talent application

[PDF] B ibihothèque L a Fontaine

[PDF] B ibliog ra phie 1. JP Pérez, Optique géométrique et ondulatoire

[PDF] B iologie de l`insuffisance surrénale

[PDF] B ioRefine ulletin - Gestion De Projet

[PDF] B LESS ED MARGA RET CATH OL IC CO MMU NITY

[PDF] B M1 M3 M4 B1 B2 M M2 RER A RER A - Anciens Et Réunions

[PDF] b Maladie des griffes du chat Maladie des griffes du chat - Garderie Et Préscolaire

[PDF] B O N N E A N N E E - France

[PDF] B onde co mmande in fo rm a tiq ueet In te rn et Bon de commande - Cartes De Crédit

[PDF] B Paintstik® MARKER 1 White, ½ Hex Blue, ½ Hex White - Des Gants

[PDF] B PAUL-CORNU NAD Berlin Aout 2015